<DOC>
	<DOCNO>NCT03104413</DOCNO>
	<brief_summary>The objective Study M15-991 evaluate efficacy safety risankizumab versus placebo induction therapy subject moderately severely active CD .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Risankizumab Subjects With Moderately Severely Active Crohn 's Disease Who Failed Prior Biologic Treatment</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Male female age &gt; =18 &lt; = 80 year Baseline Visit . Where locally permissible , subject 16 &lt; 18 year age meet definition Tanner stage 5 development Baseline Visit Diagnosis CD least 3 month prior Baseline Confirmed diagnosis moderate severe CD assess stool frequency ( SF ) , abdominal pain ( AP ) score , Simple Endoscopic Score Crohn 's Disease ( SESCD ) Demonstrated intolerance inadequate response biologic therapy CD If female , subject must meet contraception recommendation Subject current diagnosis ulcerative colitis indeterminate colitis Subjects unstable dos concomitant Crohn 's disease therapy Receipt Crohn 's disease approve biologic agent ( within 8 week prior Baseline ) , investigational biologic agent procedure within minimally 35 day prior Baseline Prior exposure p40 inhibitor ( e.g. , ustekinumab [ Stelara ] ) p19 inhibitor ( e.g. , risankizumab ) Complications Crohn 's disease ( stricture , stenosis , short bowel , etc ) Having ostomy ileoanal pouch</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>BI 655066</keyword>
	<keyword>ABBV-066</keyword>
</DOC>